Vincerx: Compelling Clinical Efficacy of Enitociclib-Venetoclax-Prednisone Combo in Lymphoma

 Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone

Vincerx remains on target to report early clinical data from lead VersAptx™ platform compounds, VIP236 (early 2024) and VIP943 (mid 2024)

https://www.globenewswire.com/news-release/2024/01/07/2805016/0/en/Vincerx-Pharma-Announces-Compelling-Clinical-Efficacy-of-Enitociclib-in-Combination-with-Venetoclax-and-Prednisone-in-Lymphoma.html